Wednesday, July 16, 2025 7/16/2025

IN VIVO OCULAR ANGIOGENESIS ASSAY

Award Number: R44EY016254
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2005
PERIOD OF PERFORMANCE END DATE: 08/31/2010

Group Awards By:

View Award Description

IN VIVO OCULAR ANGIOGENESIS ASSAY - DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the two leading causes of blindness in adults in the industrialized world. Both conditions involve vascular abnormalities, proliferation and leakage of new blood vessels. Retinopathy of prematurity (ROP) is a major cause of newborn blindness in premature infants maintained by oxygen supplementation during the postnatal period. This disease involves intense neovascularization of the retina and leads to retinal detachment. Another cause of blindness is corneal neovascularization, which often results from injury and infection in the cornea. Current mammalian models for ocular neovascularization require lengthy, tedious surgical manipulation and do not always result in improved vision; an alternative rapid, less invasive animal model for studying the process of ocular neovascularization and assessing drug effects will facilitate identification of new therapeutics. Using zebra fish, Phase I research developed a micro plate assay for quantifying effects of angiogenic compounds on ocular neovascularization. Phase II research will perform a pilot screen of available commercially compounds and confirm positive "hits" identified in conventional animal models. Phase II research will further validate the utility of the zebra fish model for screening drugs for treating debilitating diseases involving neovascularization. By providing a quantitative in vivo assay for assessing drug effects on ocular neovascularization, the proposed zebra fish assay will facilitate development of therapeutic drugs for treating debilitating diseases involving neovascularization.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2009 ( Subtotal = $457,456 )
2009	2009	PHYLONIX PHARMACEUTICALS, INC	100 INMAN STREET SUITE 300	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Trans-NIH Recovery Act Research Support	000	3	6/5/2009	SUPPLEMENT FOR EXPANSION	$49,280
2009	2009	PHYLONIX PHARMACEUTICALS, INC	100 INMAN STREET SUITE 300	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Vision Research	001	4	9/1/2009	NON-COMPETING CONTINUATION	$408,176
														Subtotal = $457,456

Issue Date FY: 2008 ( Subtotal = $334,807 )
2008	2008	PHYLONIX PHARMACEUTICALS, INC	100 INMAN STREET SUITE 300	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Vision Research	000	3	9/11/2008	NON-COMPETING CONTINUATION	$334,807
														Subtotal = $334,807

Issue Date FY: 2007 ( Subtotal = $202,041 )
2007	2007	PHYLONIX PHARMACEUTICALS, INC	100 INMAN STREET SUITE 300	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Vision Research	000	2	9/25/2007	COMPETING CONTINUATION	$202,041
														Subtotal = $202,041

Grand Total All Awards = $994,304

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IN VIVO OCULAR ANGIOGENESIS ASSAY

Award Number: R44EY016254

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2005

PERIOD OF PERFORMANCE END DATE: 08/31/2010

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer